← Back to patent-cliff list
Vorolanib
Tier C — Watch / tradeVorolanib
Tyrogenex Inc
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：VEGFR2, KIT, PDGFR, FLT3, RET, JAK1
Brand：DURAVYU™
Indications (approved)：Renal cell carcinoma
Regional status
US
Phase III
2024-10-22
EU
Phase III
2024-11-27
China
Approved
2023-06-07
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Vorolanib?
Approved indications include: Renal cell carcinoma.
When does the Vorolanib patent expire?
No public expiry year is available for Vorolanib yet; this page updates once verified.
How do I get a quote for Vorolanib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27